91ÖÆƬ³§

Indications For Use: Gel-One Hyaluronate is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to non-pharmacologic therapy, non-steroidal anti-inflammatory drugs (NSAIDs) or simple analgesics, e.g., acetaminophen.Ìý

Ìý

Important Safety Information: Before using Gel-One Hyaluronate, tell your doctor if you are allergic to hyaluronan products, cinnamon, or products from birds such as feathers, eggs, and poultry. Gel-One Hyaluronate is only for injection into the knee, performed by a doctor or other qualified health care professional. You should not receive Gel-One Hyaluronate injection if you have a skin disease or infection around the area where the injection will be given. Gel-One Hyaluronate has not been tested to show pain relief in joints other than the knee and for conditions other than OA. Gel-One Hyaluronate has not been tested in patients who are pregnant, mothers who are nursing, or anyone under the age of 21. You should tell your doctor if you think you are pregnant or if you are nursing a child. Talk to your doctor before resuming strenuous or pro-longed weight-bearing activities after treatment. The effectiveness of repeat treatment cycles of Gel-One Hyaluronate has not been established. The side effects most commonly seen after injection of Gel-One Hyaluronate in the clinical trial were knee pain, swelling, and/or fluid build-up around the knee. These reactions are generally mild and do not last long. If any of these symptoms or signs appear after you are given Gel-One Hyaluronate or if you have any other problems, you should call your doctor. Ask your surgeon if you are a candidate and discuss potential risks. For additional information, call 1-800-447-5633, or visit www.zimmerbiomet.com.ÌýÌý

Indications For Use: VISCO-3 Sodium Hyaluronate is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen.Ìý

Ìý

Important Safety Information: Before using VISCO-3 Sodium Hyaluronate, ask your patients if they are allergic to hyaluronan products, or products from birds such as feathers, eggs, and poultry. Do not administer to patients with known hypersensitivity to sodium hyaluronate preparations. Use caution when injecting VISCO-3 Sodium Hyaluronate into patients who are allergic to avian proteins, feathers and egg products. VISCO-3 Sodium Hyaluronate is only for injection into the knee, performed by a doctor or other qualified health care professional. VISCO-3 Sodium Hyaluronate injection should not be used in the presence of a skin disease or infection around the area where the injection will be given. VISCO-3 Sodium Hyaluronate has not been tested to show pain relief in joints other than the knee and for conditions other than OA. VISCO-3 Sodium Hyaluronate has not been tested in patients who are pregnant, mothers who are nursing, or anyone under the age of 21. Strenuous or pro-longed weight-bearing activities after treatment are not recommended. The effectiveness of repeat treatment cycles of VISCO-3 Sodium Hyaluronate has not been established. The side effects most commonly seen after injection of VISCO-3 Sodium Hyaluronate in the clinical trial were knee pain, swelling, and/or fluid build-up around the knee. These reactions are generally mild and do not last long. Other conditions, including but not limited to skin redness and rash, knee stiffness were also reported. For complete instructions for use, see the package insert and visit www.zimmerbiomet.com.Ìý

Indication: Anticoagulant Citrate Dextrose Solution, Solution A, U.S.P. (ACD-A) is intended for use as an anticoagulant in the extracorporeal blood processing with Autologous Platelet-Rich Plasma (PRP) Systems in production of PRP.Ìý

Ìý

Warnings and Contraindications: ACD-A is not for direct intravenous infusion.ÌýÌý

Ìý

Adverse Reactions: Not applicable. This product is used as an anticoagulant in the extracorporeal blood processing with Autologous PRP Systems in production of platelet rich plasma (PRP).Ìý

Ìý

This material is intended for US Health Care Professionals.Ìý

ACD-A Anticoagulant Citrate Dextrose Solution, Solution AÌý

Ìý

Citra Labs, LLCÌýÌý

55 Messina DriveÌýÌý

Braintree, MAÌýÌý

02184 USAÌý

Ìý

Gel-One® and VISCO-3â„¢ Sodium Hyaluronate are registered trademarks of Seikagaku Corporation.Ìý